CompuGroup Medical SE & Co. KGaA
CompuGroup Medical SE & Co. KGaA Fundamental Analysis
CompuGroup Medical SE & Co. KGaA (COP.DE) shows weak financial fundamentals with a PE ratio of 263.62, profit margin of 0.75%, and ROE of 0.68%. The company generates $0.6B in annual revenue with weak year-over-year growth of -2.84%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 13.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze COP.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakCOP.DE struggles to generate sufficient returns from assets.
Valuation Score
ModerateCOP.DE shows balanced valuation metrics.
Growth Score
WeakCOP.DE faces weak or negative growth trends.
Financial Health Score
ModerateCOP.DE shows balanced financial health with some risks.
Profitability Score
ModerateCOP.DE maintains healthy but balanced margins.
Key Financial Metrics
Is COP.DE Expensive or Cheap?
P/E Ratio
COP.DE trades at 263.62 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, COP.DE's PEG of -6.62 indicates potential undervaluation.
Price to Book
The market values CompuGroup Medical SE & Co. KGaA at 1.80 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.33 times EBITDA. This is generally considered low.
How Well Does COP.DE Make Money?
Net Profit Margin
For every $100 in sales, CompuGroup Medical SE & Co. KGaA keeps $0.75 as profit after all expenses.
Operating Margin
Core operations generate 9.59 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.68 in profit for every $100 of shareholder equity.
ROA
CompuGroup Medical SE & Co. KGaA generates $0.22 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
CompuGroup Medical SE & Co. KGaA produces operating cash flow of $118.54M, showing steady but balanced cash generation.
Free Cash Flow
CompuGroup Medical SE & Co. KGaA generates strong free cash flow of $88.27M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.71 in free cash annually.
FCF Yield
COP.DE converts 7.53% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
263.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-6.62
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.80
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.97
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.27
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.12
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.007
vs 25 benchmark
ROA
Return on assets percentage
0.002
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How COP.DE Stacks Against Its Sector Peers
| Metric | COP.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 263.62 | 28.81 | Worse (Expensive) |
| ROE | 0.68% | 643.00% | Weak |
| Net Margin | 0.75% | -44312.00% (disorted) | Weak |
| Debt/Equity | 1.27 | 0.36 | Weak (High Leverage) |
| Current Ratio | 1.12 | 4.50 | Neutral |
| ROA | 0.22% | -17799.00% (disorted) | Weak |
COP.DE outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews CompuGroup Medical SE & Co. KGaA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
44.79%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-50.81%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
9.15%
Industry Style: Defensive, Growth, Innovation
Growing